Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

127.36 -0.15 (-0.11%)
Streaming Delayed Price Updated: 11:22 AM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024
Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD. 
Via Talk Markets
Gilead Sciences Stock Crashes 9% After Cancer Drug Fails A Key Test
The company had hoped Trodelvy would extend overall survival for patients with a form of lung cancer. 
Via Investor's Business Daily
7 Exciting Stocks Poised for Explosive Growth in Key Sectors
These stocks to buy for growth already have a strong growth story. If they reach their potential investors could see some dynamic returns. 
Via InvestorPlace
Week in Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy
Lee’s Pharma acquired China rights to a heart failure therapy from Windtree Therapeutics. Meanwhile, AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech... 
Via Talk Markets
Smart Money Is Betting Big In MRK Options
Via Benzinga
Peering Into Merck & Co's Recent Short Interest
Via Benzinga
Demystifying Merck & Co: Insights From 9 Analyst Reviews
Via Benzinga
S&P 500 Shatters Records: The Top-Performing Stocks In January 2024
2023 was a historical milestone for S&P 500 as it once again surpassed record highs, largely due to tech giants and artificial intelligence. Top gainers were NVIDIA, Meta Platforms, and AMD. 
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Amgen's Blockbuster Osteoporosis Drug Prolia Flagged With FDA Strictest Warning
FDA issues serious warning on Amgen's Prolia drug, highlighting increased risk of low calcium levels in specific patient groups. 
Via Benzinga
Exposures Product Safety
Why Is Cancer Focused Adagene Stock Plummeting Today?
Adagene presents results at ASCO 2024 Gastrointestinal Cancers Symposium. ADG126, combined with Merck's Keytruda, shows limited toxicity, sustained partial responses, and a 22% overall response rate in... 
Via Benzinga
The 3 Best Dividend Growth Stocks to Buy in January 2024
These are the best dividend growth stocks to buy as they represent companies with healthy free cash flow upside visibility. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Merck's Crown Jewel Cancer Drug Keytruda Scores FDA Approval For Third Indication In Cervical Cancer
FDA approves Merck's Keytruda for advanced cervical cancer. Keytruda plus chemoradiotherapy shows a 41% improvement in progression-free survival. 
Via Benzinga
Exposures Product Safety
7 Healthcare Stocks Taking Medicine to the Next Level
With advances in technology potentially able to improve the human condition, these are the compelling healthcare stocks to consider. 
Via InvestorPlace
These 9 Stocks Are Running To Start 2024
The S&P 500 is up just 0.2% in 2024. These stocks are off to a strong start. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut. 
Via Investor's Business Daily
Topics ETFs
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease. 
Via Investor's Business Daily
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the  
Via Benzinga
The 3 Best Blue-Chip Stocks to Buy in January 2024
With a history of consistent shareholder returns, the best blue-chip stocks will reward patient investors in 2024. 
Via InvestorPlace
2024 Marks a New Era Of Pharmaceutical Innovation
With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefine their business focus last year, and so, they turned... 
Via Benzinga
Exposures COVID-19
Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today?
Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an  
Via Benzinga
Today Is Cancer-Focused Deals Day: Johnson & Johnson Scoops Up Ambrx Biopharma As Merck Boosts Cancer Portfolio With Harpoon Deal
Monday, Johnson & Johnson (NYSE: JNJ) has agreed to acquire Ambrx Biopharma Inc (NASDAQ: AMAM) in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billi 
Via Benzinga
Health Care Company Merck & Co Announces Acquisition of Harpoon Therapeutics
Via Benzinga
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value
The year's biggest medical conference kicked off with a melee of buyout news. 
Via Investor's Business Daily
Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?
Shares shot 7% higher in the first week of 2024 as excitement grows for its late-stage pipeline. 
Via Investor's Business Daily
Why Is Harpoon Therapeutics (HARP) Stock Up 111% Today?
Harpoon Therapeutics stock is rocketing higher on Monday as HARP investors react to Merck acquiring the company for $23 per share. 
Via InvestorPlace
Why Is Cancer Focused Harpoon Therapeutics Stock Shooting Higher Today?
Merck & Co Inc (NYSE: MRK) is reportedly negotiating to purchase cancer drugmaker Harpoon Therapeutics Inc (NASDAQ:  
Via Benzinga
Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks This Year?
These four names span different sectors, but all underperformed in 2023. Is it time to be a contrarian and pick up bargains on the discount aisle? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Wall Street's Top 10 Stock Calls This Week - Saturday, Jan. 6
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the week of Jan. 2-5. 
Via Talk Markets
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.  
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.